| Literature DB >> 30724735 |
Ruth Dubin1,2, Anna Rubinsky3.
Abstract
BACKGROUND: Patient education regarding end-stage renal disease (ESRD) has the potential to reduce adverse outcomes and increase the use of in-home renal replacement therapies.Entities:
Keywords: chronic kidney disease; end-stage renal disease; online social networking; patient education; renal dialysis
Year: 2019 PMID: 30724735 PMCID: PMC6381409 DOI: 10.2196/12528
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Figure 1Recruitment and enrollment. A total of 2617 patients who had been seen at the University of California, San Francisco and San Francisco Veterans Affairs Medical Center renal clinics were either sent letters to notify them of the study or screened via the electronic medical record for eligibility. A total of 156 patients were potentially eligible based on initial screening; of these, we found 98 of those that responded to be eligible after the phone interview. Moreover, 27 of these enrolled into the study and 25 completed the study.
Baseline characteristics of participants (N=25).
| Characteristic | Statisticsa | |
| Age (years), mean (SD) | 65 (15) | |
| Female, n (%) | 8 (32) | |
| Latino, n (%) | 2 (8) | |
| Black | 5 (20) | |
| White | 12 (48) | |
| Other | 8 (32) | |
| Employed full- or part-time | 6 (23) | |
| Retired | 13 (52) | |
| Unemployed | 3 (12) | |
| Disability, n (%) | 2 (8) | |
| <25,000 | 9 (36) | |
| 25,000-49,999 | 4 (16) | |
| 50,000-99,999 | 4 (16) | |
| >100,000 | 6 (24) | |
| High school diploma or general education diploma | 4 (16) | |
| Associate’s degree | 1 (4) | |
| Bachelor’s degree | 9 (36) | |
| Master’s degree | 4 (16) | |
| Doctorate | 3 (12) | |
| Uses the internet on shared or public computer, n (%) | 3 (12) | |
| Diabetes, n (%) | 17 (68) | |
| Prior or current tobacco use, n (%) | 14 (56) | |
| Time since CKDb diagnosis (years), median (IQRc) | 10 (4-23) | |
| Estimated glomerular filtration rate (ml/min/1.73 m2), mean (SD) | 21 (6) | |
| Glomerulonephritis | 5 (20) | |
| Diabetes | 4 (16) | |
| Hypertension | 3 (12) | |
| Medication adverse effect | 2 (8) | |
| Vasculitis | 1 (4) | |
| Polycystic kidney disease | 1 (4) | |
| Unknown | 9 (36) | |
| Peritoneal dialysis | 1 (4) | |
| Hemodialysis | 6 (24) | |
| Vascular access, n (%) | 3 (12) | |
| Evaluated for transplant, n (%) | 13 (52) | |
| Active on transplant list, n (%) | 7 (28) | |
| 5-8 months | 2 (8) | |
| 9-12 months | 3 (12) | |
| >12 months | 20 (80) | |
| Agree or strongly agree | 12 (48) | |
| Neutral or unsure | 7 (28) | |
| Disagree or strongly disagree | 6 (24) | |
aCategorical data are shown as n (%); continuous data are summarized as mean (SD) or median (IQR). All data were collected via self-report.
bCKD: chronic kidney disease.
cIQR: interquartile range.
Participation and engagement during the 4-week educational program (N=25).
| Measure | Statisticsa | |
| Days required to complete program, mean (SD) | 32 (14) | |
| Hours active on program, median (IQRb) | 5 (2-6) | |
| Viewed at least one video, n (%) | 24 (96) | |
| Number of unique videos viewed (out of 9), median (IQR) | 8 (5-9) | |
| Total number of video views), median (IQR) | 10 (8-21) | |
| Viewed at least one frequently asked question, n (%) | 25 (100) | |
| Number of unique frequently asked questions viewed (out of 129), median (IQR) | 24 (10-98) | |
| Total number of frequently asked question views, median (IQR) | 32 (15-118) | |
| Number of messages sent to nurse, mentors, or discussion board, median (IQR) | 11 (4-19) | |
| Number of conversations viewed on discussion board, median (IQR) | 27 (13-47) | |
| Chatted with nurse, n (%) | 21 (84) | |
| Chatted with mentor, n (%) | 6 (24) | |
| Chatted with group, n (%) | 11 (44) | |
aCategorical data are shown as n (%); continuous data are summarized as mean (SD) or median (IQR). Data were collected by Cricket Health.
bIQR: interquartile range.
Preferred treatment modality choice, if transplant is a feasible choice.
| Treatment choice | n (%)a | |
| Kidney transplant | 12 (48) | |
| Conservative management | 2 (8) | |
| Peritoneal dialysis | 1 (4) | |
| Home hemodialysis | 1 (4) | |
| In-center hemodialysis | 1 (4) | |
| None/unsure | 8 (32) | |
| Kidney transplant | 21 (84)b | |
| Conservative management | 2 (8) | |
| Peritoneal dialysis | 1 (4) | |
| Home hemodialysis | 1 (4) | |
| In-center hemodialysis | 0 (0) | |
| None/unsure | 0 (0) | |
| Kidney transplant | 19 (79) | |
| Conservative management | 2 (8) | |
| Peritoneal dialysis | 1 (4) | |
| Home hemodialysis | 2 (8) | |
| In-center hemodialysis | 0 (0) | |
| None/unsure | 0 (0) | |
aCategorical data are shown as n (%). Data obtained from surveys conducted at intake of each study participant, after 4 weeks of engagement and completion of the Modality Decision Program, and then 4 weeks after completing the Modality Decision Program.
bP value for tested differences in proportions between initial and month 1 survey, using McNemar exact test was .01.
Preferred treatment modality choice, if transplant is not a feasible choice.
| Treatment choice with transplant option removed | n (%)a | |
| —c | ||
| Conservative management | 6 (24) | |
| Peritoneal dialysis | 4 (16) | |
| Home hemodialysis | 2 (8) | |
| In-center hemodialysis | 5 (20) | |
| None/unsure | 8 (32) | |
| — | ||
| Conservative management | 6 (24) | |
| Peritoneal dialysis | 13 (52)d | |
| Home hemodialysis | 4 (16)e | |
| In-center hemodialysis | 2 (8) | |
| None/unsure | 0 (0) | |
| — | ||
| Conservative management | 3 (13) | |
| Peritoneal dialysis | 12 (50) | |
| Home hemodialysis | 6 (25) | |
| In-center hemodialysis | 3 (13) | |
| None/unsure | 0 (0) | |
aCategorical data are shown as n (%). Data obtained from surveys conducted at intake of each study participant, after 4 weeks of engagement and completion of the Modality Decision Program, and then 4 weeks after completing the Modality Decision Program.
bIn a post hoc analysis, we determined patients’ preferred treatment choice in the case that a kidney transplant was not available or feasible (eg, with that answer option excluded).
cNot applicable.
dP value for tested differences in proportions between initial and month 1 survey, using McNemar exact test was .004.
eP value for tested differences in proportions between initial and month 1 survey, using McNemar exact test was .50.
Chronic kidney disease knowledge, confidence, and self-efficacy.
| Measure | Statisticsa | |||
| <.001 | ||||
| Initial survey, mean (SD) | 65 (56) | |||
| Month 1 survey (main effect), mean (SD) | 83 (14) | |||
| Month 2 survey (durability), mean (SD) | 86 (11) | |||
| Patients who improved after program, n (%) | 19 (76) | |||
| .03 | ||||
| Initial survey, mean (SD) | 3.2 (1.4) | |||
| Month 1 survey, mean (SD) | 4.1 (1.0) | |||
| Month 2 survey, mean (SD) | 4.3 (0.7) | |||
| Patients who improved after program, n (%) | 15 (60) | |||
| <.001 | ||||
| Initial survey, mean (SD) | 3.7 (0.7) | |||
| Month 1 survey, mean (SD) | 4.3 (0.5) | |||
| Month 2 survey, mean (SD) | 4.3 (0.6) | |||
| Patients who improved after program, n (%) | 20 (80) | |||
| .12 | ||||
| Initial survey, mean (SD) | 4.1 (0.6) | |||
| Month 1 survey, mean (SD) | 4.2 (0.6) | |||
| Month 2 survey, mean (SD) | 4.1 (0.9) | |||
| Patients who improved after program, n (%) | 5 (20) | |||
| .002 | ||||
| Initial survey, mean (SD) | 3.6 (0.8) | |||
| Month 1 survey, mean (SD) | 4.3 (0.6) | |||
| Month 2 survey, mean (SD) | 4.3 (0.6) | |||
| Patients who improved after program, n (%) | 14 (56) | |||
| .06 | ||||
| Initial survey, mean (SD) | 4.2 (0.6) | |||
| Month 1 survey, mean (SD) | 4.4 (0.7) | |||
| Month 2 survey, mean (SD) | 4.5 (0.5) | |||
| Patients who improved after program, n (%) | 6 (24) | |||
| <.001 | ||||
| Initial survey, mean (SD) | 3.1 (1.2) | |||
| Month 1 survey, mean (SD) | 4.2 (0.8) | |||
| Month 2 survey, mean (SD) | 4.2 (0.6) | |||
| Patients who improved after program, n (%) | 16 (64) | |||
| .005 | ||||
| Initial survey, mean (SD) | 3.4 (1.3) | |||
| Month 1 survey, mean (SD) | 4.2 (0.6) | |||
| Month 2 survey, mean (SD) | 4.2 (0.7) | |||
| Patients who improved after program, n (%) | 12 (48) | |||
aCategorical data are shown as n (%); continuous data (scores) are summarized as mean (SD). Data obtained from surveys.
bP value calculated by Wilcoxon signed-rank test for the difference between initial values and values at month 1 study visit.
cCKD: chronic kidney disease.
dSelf-efficacy statement drawn from CKD Self-Efficacy instrument developed by Lin et al [17].